Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis

Summary

Although the control of thrombin in the microvasculature at the endothelial cell surface is crucial to prevent atherothrombosis, the role of antithrombin in arterial thrombosis is unclear. It is widely considered that antithrombin deficiency is unlikely to contribute to arterial thrombosis, but no convincing epidemiological study has been performed because of the low frequency of this deficiency. In this study we evaluated the role in myocardial infarction (MI) of a relatively common mutation affecting antithrombin gene (A384S: Antithrombin Cambridge II) that has functional features that may impair the right control of thrombogenic events caused by injury to the vascular wall. Moreover, this deficiency, which is not detected using common methods to diagnose antithrombin deficiency, also increases the risk of venous thrombosis. We included 1,224 patients with MI (691 consecutive patients and 533 survivors of a premature event), and 1,649 controls. The mutation was identified in 0.3% of controls, but 0.8% of MI patients. After adjusting for sex and other cardiovascular risk factors, the antithrombin Cambridge II significantly increased 5.66-fold the risk of MI (95% CI: 1.53–20.88; p= 0.009). Interestingly, young patients had the highest risk of MI associated with the mutation (OR: 9.98; 95%CI: 1.60–62.24; p= 0.009). This is the first epidemiological study that supports a role for anti-thrombin deficiency in arterial thrombosis. These results suggest that deficiency of antithrombin may be an independent risk factor for MI that has been underestimated, but larger studies are needed to confirm the relevance of inhibitors of thrombin in arterial thrombosis.

Keywords

Genetics - myocardial infarction - thrombosis - risk factors - anticoagulants

• References

• 1 de Moerloose P, Boehlen F. Inherited thrombophilia in arterial disease: a selective review. Semin Hematol 2007; 44: 106-113.
• 2 Ye Z, Liu EH, Higgins JP. et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006; 367: 651-658.
• 3 Casas JP, Hingorani AD, Bautista LE. et al. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch Neurol 2004; 61: 1652-1661.
• 4 Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-264.
• 5 Ishiguro K, Kojima T, Kadomatsu K. et al. Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest 2000; 106: 873-878.
• 6 Franco RF, Reitsma PH. Gene polymorphisms of the haemostatic system and the risk of arterial thrombotic disease. Br J Haematol 2001; 115: 491-506.
• 7 Conard J, Samama MM. Inhibitors of coagulation, atherosclerosis, and arterial thrombosis. Semin Thromb Hemost 1986; 12: 87-90.
• 8 Coller BS, Owen J, Jesty J. et al. Deficiency of plasma protein S, protein C, or antithrombin III and arterial thrombosis. Arteriosclerosis 1987; 7: 456-462.
• 9 Chowdhury V, Lane DA, Mille B. et al. Homozygous antithrombin deficiency: report of two new cases (99 Leu to Phe) associated with arterial and venous thrombosis. Thromb Haemost 1994; 72: 198-202.
• 10 Brown SA, Mitchell M, Cutler JA. et al. Rapid genetic diagnosis in neonatal pulmonary artery thrombosis caused by homozygous antithrombin Budapest 3. Clin Appl Thromb Hemost 2000; 6: 181-183.
• 11 Tait RC, Walker ID, Perry DJ. et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87: 106-112.
• 12 Corral J, Hernandez-Espinosa D, Soria JM. et al.. Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. Blood 2007; 109: 4258-4263.
• 13 Giacomelli SH, Simioni M, Madeo D. et al. Anti-thrombin deficiency in the general population is rarely due to AT gene mutations, which are mainly represented by Ala384Ser mutation. J Thromb Haemost. 2007 5 (Suppl 2): P-M-467.
• 14 Perry DJ, Daly ME, Tait RC. et al. Antithrombin Cambridge II (Ala384Ser): clinical, functional and haplotype analysis of 18 families. Thromb Haemost 1998; 79: 249-253.
• 15 Barba P, Santamaría A, Tirado I. et al. Antithrombin Cambridge II mutation as a risk factor to develop cerebral venous thrombosis. Thromb Haemost 2008; 99: 443-444.
• 16 Joint European Society of Cardiology/American College of Cardiology Committee.. Myocardial infarction redefined. A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000; 21: 1502-1513.
• 17 Anderson KM, Wilson PW, Odell PM. et al. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356-362.
• 18 Pathak A, Zhao R, Monroe DM. Roberts et al. Thrombin generation in vascular tissue. J Thromb Haemost 2006; 4: 60-67.
• 19 Andreotti F, Testa L, Biondi-Zoccai GGL. et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25307 patients. Eur Heart J 2006; 27: 519-526.
• 20 Husmann M, Barton M. Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease. Expert Opin Investig Drugs 2007; 16: 563-567.
• 21 He L, Vicente CP, Westrick RJ. et al. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest 2002; 109: 213-219.
• 22 Aihara K, Azuma H, Akaike M. et al.. Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient mice. J Clin Invest 2007; 117: 1514-1526.
• 23 de Agostini AI, Watkins SC, Slayter HS. et al. Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta. J Cell Biol 1990; 111: 1293-1304.
• 24 McCoy AJ, Pei XY, Skinner R. et al. Structure of beta-antithrombin and the effect of glycosylation on antithrombin’s heparin affinity and activity. J Mol Biol 2003; 326: 823-833.
• 25 Frebelius S, Isaksson S, Swedenborg J. Thrombin inhibition by antithrombin III on the subendothelium is explained by the isoform AT?. Arterioscler Thromb Vasc Biol 1996; 16: 1292-1297.
• 26 Witmer MR, Hatton MW. Antithrombin III-beta associates more readily than antithrombin III-alpha with uninjured and de-endothelized aortic wall in vitro and in vivo. Arterioscler Thromb 1991; 11: 530-539.
• 27 Leng B, Lu A, Riesenfeld J. et al. Enhanced heparin binding affinities increase the efficiencies at which the beta-antithrombin III isoform and a recombinant ATIII variant load onto pentasaccharide-bearing surfaces under flow. J Thromb Haemost. 2007 5 (Suppl 2): P-W-053.
• 28 Williams MJ, Restieaux NJ, Low CJS. Myocardial infarction in young people with normal coronary arteries. Heart 1998; 79: 191-194.
• 29 Mushunje A, Zhou A, Carrell RW. et al. Heparin-induced substrate behaviour of antithrombin Cambridge II. Blood 2003; 102: 4028-4034.
• 30 D’hondt C. Role for heparan sulfate proteoglycan in thrombin-induced calcium transients and nitric oxide production in aortic endothelial cells. Thromb Haemost 2008; 100: 374-376.